# Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

> **NCT05755386** · PHASE3 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 106 (estimated)

## Conditions studied

- IC-MPGN

## Interventions

- **DRUG:** Placebo
- **DRUG:** iptacopan

## Key facts

- **NCT ID:** NCT05755386
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-02
- **Primary completion:** 2028-10-27
- **Final completion:** 2029-05-31
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05755386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05755386, "Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05755386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*